4//SEC Filing
Omthera Pharmaceuticals, Inc. 4
Accession 0001181431-13-040547
CIK 0001477598operating
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 2:55 PM ET
Size
5.7 KB
Accession
0001181431-13-040547
Insider Transaction Report
Form 4
SANDELL SCOTT D
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2013-07-18−5,833,213→ 0 total(indirect: See Note 3)
Footnotes (3)
- [F1]David M. Mott serves as a representative of New Enterprise Associates 13, L.P. ("NEA 13") and its affiliates on the board of directors of Omthera Pharmaceuticals, Inc. (the "Company") as a director by deputization.
- [F2]Pursuant to the Agreement and Plan of Merger by and among the Company, Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013, each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
- [F3]The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of NEA 13, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the securities held by NEA 13, except to the extent of his pecuniary interest therein.
Documents
Issuer
Omthera Pharmaceuticals, Inc.
CIK 0001477598
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001477598
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 2:55 PM ET
- Size
- 5.7 KB